Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian for Prevention of Ischemic Stroke After Acute Ischemic Stroke or High-risk TIA (Phase III, China)
CTR20233526Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and transient ischaemic attack (TIA) comparing Milvexian arm with Placebo arm (2 arms). Primary endpoint: Time to first ischemic stroke (primary endpoint, to global target end date). Started Dec 2023; status: active.
02
Drugs
milvexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on CTR20233526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233526.